Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti-VEGF PRS-050 is first Anticalin tested in humans
Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. ...